



ASX Announcement / Media Release

ABN: 80 063 114 045
Level 1, 18 Kavanagh Street
Southbank, Vic 3006
Tel: +61 (0)3 8648 4530
Fax: +61 (0)3 9686 9460
www.immuron.com

IMMURON ALLOWED TRAVELAN PATENT IN THE UNITED STATES

Wednesday 23 October 2013, Melbourne, Australia: Immuron Limited (ASX:IMC) today announced that it has received a Notice of Allowance for a key patent by the United States Patents and Trademarks Office (USPTO). Immuron's patent claims are directed to methods of treating enteric diseases caused by gram negative bacteria with the use of Immuron's hyperimmune colostrum platform technology.

Enteric diseases include those caused by pathogens entering the body through the mouth or gastrointestinal system. A large group of such bacteria includes Escherichia coli (E. coli), Salmonella, Shigella, Helicobacter and Legionella. These bacteria have been implicated in chronic diseases such as Irritable Bowel Disease and Non-Alcoholic Steatohepatitis, known as NASH. Hence, the breadth of Immuron's patent protection encompasses Travelan® as well as a range of other products.

The global markets for treatment of these chronic diseases is estimated in the order of magnitude of \$Billions annually. Immuron's patent is expected to support Immuron's competitive advantages in these markets.

Amos Meltzer, Immuron's CEO, said: "The timing of the patent allowance is auspicious as we continue to progress with our substantive discussions in the United States for the commercialization of Travelan and related products in the world's largest market for pharmaceuticals. It is reassuring to have this patent in place, along with our substantial library of proprietary trade secrets and complementary patent rights.

We look forward to achieving further patents around our core technologies in the USA and other key jurisdictions".

Contact

Amos Meltzer
Chief Executive Officer
Immuron Limited

+61 (0)3 8648 4530

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron's products will be expedited. Immuron's current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver/NASH, and influenza. Immuron has a product in the market, Travelan, for preventing travellers' diarrhoea.